Published in J Clin Invest on August 01, 2002
Obstructive nephropathy: insights from genetically engineered animals. Kidney Int (2005) 1.97
Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest (2009) 1.54
Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost (2009) 1.10
The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int (2009) 1.04
Congenital ureteropelvic junction obstruction: human disease and animal models. Int J Exp Pathol (2010) 0.99
Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition. Am J Physiol Renal Physiol (2008) 0.95
The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis. Genes Immun (2009) 0.93
Blockade of the kinin B1 receptor ameloriates glomerulonephritis. J Am Soc Nephrol (2010) 0.91
Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol (2004) 0.91
The kallikrein-kinin system in diabetic nephropathy. Kidney Int (2012) 0.90
Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One (2012) 0.90
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair (2011) 0.87
Balance between the two kinin receptors in the progression of experimental focal and segmental glomerulosclerosis in mice. Dis Model Mech (2014) 0.83
Impact of Mast Cell Chymase on Renal Disease Progression. Curr Hypertens Rev (2012) 0.78
Kinin B1 receptor antagonism is equally efficient as angiotensin receptor 1 antagonism in reducing renal fibrosis in experimental obstructive nephropathy, but is not additive. Front Pharmacol (2015) 0.76
Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy. Mol Cell Proteomics (2014) 0.76
Conditional knockout of collecting duct bradykinin B2 receptors exacerbates angiotensin II-induced hypertension during high salt intake. Clin Exp Hypertens (2015) 0.76
The complement factor 5a receptor 1 has a pathogenic role in chronic inflammation and renal fibrosis in a murine model of chronic pyelonephritis. Kidney Int (2016) 0.75
Kallikrein-kinin in stem cell therapy. World J Stem Cells (2014) 0.75
Development of a synthetic gene network to modulate gene expression by mechanical forces. Sci Rep (2016) 0.75
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis (1992) 3.73
Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med (1998) 3.18
The progression of renal disease. N Engl J Med (1988) 2.70
Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science (1999) 2.62
PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int (2001) 2.41
Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension (1990) 1.70
A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest (2002) 1.70
Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol (2001) 1.46
Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem (1993) 1.45
Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int (1995) 1.42
Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem (1995) 1.40
Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation (2000) 1.28
Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension (1994) 1.26
Bradykinin receptor antagonists. Med Res Rev (1990) 1.25
Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. Kidney Int (1988) 1.22
The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest (1998) 1.22
Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int (2000) 1.21
Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood (1985) 1.15
Unilateral ureteral obstruction in neonatal rats leads to renal insufficiency in adulthood. Kidney Int (2000) 1.10
Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int (1994) 1.07
Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension (1999) 1.07
Obstructive nephropathy. Kidney Int (1998) 1.05
Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol (1999) 1.04
Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int (1994) 1.03
Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J (2000) 1.02
Theodore Cooper Memorial Lecture. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension (1995) 1.00
Bradykinin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. Am J Respir Cell Mol Biol (2000) 0.99
Upregulation of renin-angiotensin system and downregulation of kallikrein in obstructive nephropathy. Am J Physiol (1993) 0.99
Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol (1999) 0.97
Mouse proximal tubular cell-cell adhesion inhibits apoptosis by a cadherin-dependent mechanism. Am J Physiol Renal Physiol (2000) 0.97
Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK. Am J Physiol Heart Circ Physiol (2000) 0.92
Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation (2002) 0.90
Therapeutic approaches in obstructive uropathy. Semin Nephrol (1998) 0.82
Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy? Drugs (1997) 0.78
Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant (1997) 0.77
Lrp5 functions in bone to regulate bone mass. Nat Med (2011) 5.33
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A (2003) 5.08
Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science (2003) 4.58
Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med (2007) 3.22
Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med (2008) 3.10
Platelet-derived serotonin mediates liver regeneration. Science (2006) 2.98
Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res (2006) 2.67
Weight loss and the renin-angiotensin-aldosterone system. Hypertension (2005) 2.58
Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev Cell (2004) 2.40
Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol (2009) 2.40
Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell (2003) 2.28
A unique central tryptophan hydroxylase isoform. Biochem Pharmacol (2003) 2.23
Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med (2002) 2.20
Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res (2006) 2.08
Urine in clinical proteomics. Mol Cell Proteomics (2008) 2.05
Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol (2011) 2.04
Using Google Earth to conduct a neighborhood audit: reliability of a virtual audit instrument. Health Place (2010) 2.03
Growth retardation and altered autonomic control in mice lacking brain serotonin. Proc Natl Acad Sci U S A (2009) 2.01
Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke (2008) 1.90
Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension (2008) 1.81
Axonal transcription factors signal retrogradely in lesioned peripheral nerve. EMBO J (2012) 1.77
Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca2+ influx via reverse-mode activity of the Na+/Ca2+ exchanger. J Neurosci (2007) 1.74
Serotonin is required for exercise-induced adult hippocampal neurogenesis. J Neurosci (2013) 1.72
Mobility disability and the urban built environment. Am J Epidemiol (2008) 1.72
The transcription factor grainyhead-like 2 regulates the molecular composition of the epithelial apical junctional complex. Development (2010) 1.68
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem (2010) 1.65
Differential use of importin-α isoforms governs cell tropism and host adaptation of influenza virus. Nat Commun (2011) 1.65
Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem (2004) 1.63
Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene. J Biol Chem (2003) 1.60
Leptin regulates ACE activity in mice. J Mol Med (Berl) (2010) 1.59
Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res (2008) 1.59
Determination of mercury in blood, urine and saliva for the biological monitoring of an exposure from amalgam fillings in a group with self-reported adverse health effects. Int J Hyg Environ Health (2002) 1.55
Reduced hypertension-induced end-organ damage in mice lacking cardiac and renal angiotensinogen synthesis. J Mol Med (Berl) (2002) 1.54
Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes (2007) 1.52
Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res (2007) 1.52
Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med (2006) 1.52
LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol (2007) 1.51
Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension (2006) 1.51
Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells (2009) 1.51
Engraftment of human T, B and NK cells in CB.17 SCID/beige mice by transfer of human spleen cells. Transpl Immunol (2005) 1.51
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension (2010) 1.50
Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol (2010) 1.48
Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension (2008) 1.48
Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol (2013) 1.48
Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors. J Mol Med (Berl) (2008) 1.47
Low immunogenicity of endothelial derivatives from rat embryonic stem cell-like cells. Cell Res (2009) 1.46
Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E. J Mol Med (Berl) (2009) 1.45
Reconsidering access: park facilities and neighborhood disamenities in New York City. J Urban Health (2011) 1.44
Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin. J Hypertens (2013) 1.44
Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One (2009) 1.43
Central control of fever and female body temperature by RANKL/RANK. Nature (2009) 1.42
SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther (2010) 1.42
Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension (2005) 1.39
Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension (2008) 1.37
Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens (2007) 1.35
Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol (1985) (2002) 1.35
Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation (2006) 1.33
Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice. Am J Physiol Renal Physiol (2004) 1.32
Isolation of Oct4-expressing extraembryonic endoderm precursor cell lines. PLoS One (2009) 1.29
Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J Cereb Blood Flow Metab (2010) 1.28
Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med (2009) 1.27
Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int (2009) 1.27
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med (2005) 1.27
Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics (2004) 1.25
Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension (2006) 1.24
Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells (2008) 1.19
Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension (2008) 1.19
Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci U S A (2006) 1.18
Down-regulation of catalase and oxidative modification of protein kinase CK2 lead to the failure of apoptosis repressor with caspase recruitment domain to inhibit cardiomyocyte hypertrophy. J Biol Chem (2008) 1.17
Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol (2004) 1.17
Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol (2002) 1.15
The FunGenES database: a genomics resource for mouse embryonic stem cell differentiation. PLoS One (2009) 1.15
Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum Mutat (2007) 1.14
Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol (2010) 1.14
Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation (2008) 1.13
Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res (2013) 1.13
Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res (2008) 1.12
Diabetic hypertensive leptin receptor-deficient db/db mice develop cardioregulatory autonomic dysfunction. Hypertension (2008) 1.12
Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension (2004) 1.12
Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension (2005) 1.12
Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension (2006) 1.12
Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J (2005) 1.11
The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics (2009) 1.11
Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology (2007) 1.11
Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res (2002) 1.10
Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol (2006) 1.10
Mouse model of fracture pain. Anesthesiology (2008) 1.10
Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood (2012) 1.09
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res (2006) 1.09
Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes (2009) 1.09
Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation (2002) 1.08
Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J (2007) 1.08
Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology (2007) 1.08
Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep (2009) 1.08
Specification and differentiation of serotonergic neurons. Stem Cell Rev (2006) 1.08
ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res (2010) 1.08
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J (2004) 1.08